^
    No biomarker
    Follicular Lymphoma
    axicabtagene ciloleucel
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    rituximab + lenalidomide
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    Truxima (rituximab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    Rixathon (rituximab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    Ruxience (rituximab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    obinutuzumab
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    rituximab
    Sensitive
    :
    A1
    CD20 positive
    Follicular Lymphoma
    rituximab + ibritumomab tiuxetan
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    ibritumomab tiuxetan
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    idelalisib
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    duvelisib
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    tazemetostat
    Sensitive
    :
    A1
    EZH2 mutation
    Follicular Lymphoma
    tazemetostat
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    copanlisib
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    umbralisib
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    lisocabtagene maraleucel
    Sensitive
    :
    A1
    CD20 positive
    Follicular Lymphoma
    Ruxience (rituximab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    R-CHOP
    Sensitive
    :
    A2
    No biomarker
    Follicular Lymphoma
    R-CVP
    Sensitive
    :
    A2
    No biomarker
    Follicular Lymphoma
    rituximab + obinutuzumab
    Sensitive
    :
    A2
    No biomarker
    Follicular Lymphoma
    lenalidomide
    Sensitive
    :
    A2
    No biomarker
    Follicular Lymphoma
    chlorambucil
    Sensitive
    :
    A2
    No biomarker
    Follicular Lymphoma
    lenalidomide + obinutuzumab
    Sensitive
    :
    A2
    No biomarker
    Follicular Lymphoma
    cyclophosphamide intravenous
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES